Streetbeat News

Revenues

LINC

Lincoln Educational Services (NASDAQ:LINC) reported Q2 earnings per share (EPS) of $(0.02), missing the analyst consensus estimate of $(0.01). However, the company reported quarterly sales of $102.91 million, beating the estimate of $100.60 million and showing a 16.10% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:06 pm

PHAT

Phathom Pharmaceuticals reported its Q2 2024 results, with an adjusted EPS of $(1.25), beating the estimate of $(1.38). Sales were $7.324 million, surpassing the expected $5.809 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:06 pm

EVAX

Evaxion Biotech A/S (NASDAQ:EVAX) will present one-year clinical efficacy data from its Phase 2 study on its lead cancer vaccine candidate, EVX-01, at the ESMO Congress 2024. The vaccine is being tested in patients with advanced melanoma.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:06 pm

MSFT

PLTR

Microsoft and Palantir have announced an expanded partnership to deploy AI tools for U.S. government agencies. The collaboration will integrate Microsoft's large language models via Azure OpenAI Service with Palantir's AI platforms in Microsoft's government cloud environments. This partnership aims to enhance AI and analytics capabilities for the U.S. Defense and Intelligence Community.

Portfolio Pulse from Benzinga Neuro

August 08, 2024 | 12:05 pm

SAVA

Cassava Sciences expects net cash use in operations for the second half of 2024 to be $80M-$90M, including a $40M loss contingency related to SEC investigation discussions. The company estimates year-end 2024 cash at $117M-$127M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:05 pm

GSAT

Globalstar (AMEX:GSAT) reported Q2 2024 GAAP EPS of $(0.01), meeting analyst expectations. The company achieved quarterly sales of $60.4 million, surpassing the $57.162 million estimate and marking a 9.67% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:05 pm

CARM

CARISMA Therapeutics (NASDAQ:CARM) reported Q2 2024 GAAP EPS of $(0.27), beating the estimate of $(0.32). Sales were $9.197M, significantly surpassing the $3.925M estimate. This represents a 44.9% improvement in EPS and a 158.34% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:04 pm

XPEL

XPEL (NASDAQ:XPEL) reported Q2 2024 adjusted EPS of $0.54, beating the estimate of $0.46 by 17.39%. Sales were $109.90M, surpassing the $105.68M estimate and showing a 7.50% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:04 pm

CION

CION Investment Corporation (NYSE:CION) reported Q2 2024 earnings per share (EPS) of $0.43, surpassing the analyst consensus estimate of $0.39 by 10.26%. The company also reported quarterly sales of $61.357 million, exceeding the estimate of $57.587 million by 6.55%. This represents a 4.89% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:04 pm

IHRT

iHeartMedia reported Q2 sales of $929.092 million, surpassing the estimated $915.977 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:04 pm